| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Myocardial Infarction | 18 | 2019 | 3361 | 1.51 | Why? |
| Uracil | 3 | 2018 | 101 | 1.47 | Why? |
| Acute Coronary Syndrome | 10 | 2018 | 2107 | 1.38 | Why? |
| Aminobutyrates | 3 | 2019 | 142 | 1.04 | Why? |
| Enalapril | 3 | 2019 | 54 | 1.01 | Why? |
| Ezetimibe | 3 | 2019 | 50 | 1.01 | Why? |
| Troponin I | 5 | 2018 | 1298 | 1.00 | Why? |
| Piperidines | 3 | 2018 | 795 | 0.95 | Why? |
| Tetrazoles | 3 | 2019 | 262 | 0.94 | Why? |
| Anticholesteremic Agents | 2 | 2019 | 186 | 0.81 | Why? |
| Troponin | 5 | 2019 | 1058 | 0.76 | Why? |
| Natriuretic Peptide, Brain | 5 | 2018 | 1215 | 0.62 | Why? |
| Diabetic Cardiomyopathies | 1 | 2017 | 79 | 0.62 | Why? |
| Adiponectin | 1 | 2017 | 123 | 0.61 | Why? |
| Cardiovascular Diseases | 10 | 2020 | 11497 | 0.61 | Why? |
| Diabetes Mellitus, Type 2 | 6 | 2018 | 6166 | 0.59 | Why? |
| Blood Chemical Analysis | 1 | 2018 | 541 | 0.53 | Why? |
| Lactones | 3 | 2019 | 62 | 0.53 | Why? |
| Double-Blind Method | 10 | 2019 | 5988 | 0.49 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2017 | 436 | 0.48 | Why? |
| Peptide Fragments | 4 | 2018 | 2075 | 0.48 | Why? |
| Heart Failure | 11 | 2019 | 6638 | 0.47 | Why? |
| Shock, Cardiogenic | 2 | 2018 | 700 | 0.45 | Why? |
| Cardiovascular System | 1 | 2019 | 750 | 0.43 | Why? |
| Biomarkers | 21 | 2020 | 23361 | 0.41 | Why? |
| Simvastatin | 3 | 2019 | 63 | 0.41 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.40 | Why? |
| Valsartan | 3 | 2019 | 206 | 0.39 | Why? |
| Cardiology | 3 | 2018 | 2873 | 0.37 | Why? |
| Secondary Prevention | 6 | 2019 | 762 | 0.37 | Why? |
| Pyridines | 3 | 2019 | 680 | 0.35 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.35 | Why? |
| Fibroblast Growth Factors | 2 | 2019 | 119 | 0.35 | Why? |
| Endpoint Determination | 3 | 2018 | 344 | 0.34 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.34 | Why? |
| Angina, Unstable | 1 | 2007 | 110 | 0.32 | Why? |
| Troponin T | 2 | 2014 | 771 | 0.31 | Why? |
| Platelet Aggregation Inhibitors | 6 | 2019 | 1671 | 0.31 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2019 | 3892 | 0.31 | Why? |
| Patient Admission | 2 | 2019 | 5250 | 0.30 | Why? |
| Creatine Kinase, MB Form | 1 | 2007 | 259 | 0.29 | Why? |
| Glomerular Filtration Rate | 3 | 2019 | 1262 | 0.26 | Why? |
| Biphenyl Compounds | 3 | 2019 | 249 | 0.26 | Why? |
| Myocardial Ischemia | 4 | 2019 | 781 | 0.25 | Why? |
| Thromboplastin | 1 | 2005 | 275 | 0.24 | Why? |
| Thrombin | 1 | 2005 | 325 | 0.23 | Why? |
| Cardiology Service, Hospital | 2 | 2020 | 602 | 0.23 | Why? |
| Thrombosis | 2 | 2020 | 7504 | 0.22 | Why? |
| Coronary Care Units | 2 | 2019 | 224 | 0.21 | Why? |
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 86 | 0.21 | Why? |
| Cystatin C | 2 | 2018 | 125 | 0.21 | Why? |
| Lipocalin-2 | 2 | 2018 | 156 | 0.20 | Why? |
| Coronary Circulation | 3 | 2018 | 188 | 0.20 | Why? |
| Cyclic GMP | 1 | 2019 | 50 | 0.20 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 92 | 0.20 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.18 | Why? |
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2017 | 2 | 0.18 | Why? |
| Aged | 32 | 2020 | 215776 | 0.18 | Why? |
| Tobacco Use Cessation | 1 | 2018 | 52 | 0.18 | Why? |
| Nicotinic Agonists | 1 | 2018 | 56 | 0.18 | Why? |
| Registries | 6 | 2021 | 12327 | 0.18 | Why? |
| Glucuronidase | 1 | 2019 | 103 | 0.18 | Why? |
| Equivalence Trials as Topic | 1 | 2018 | 242 | 0.17 | Why? |
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2018 | 92 | 0.17 | Why? |
| Ranolazine | 1 | 2017 | 17 | 0.17 | Why? |
| Neprilysin | 1 | 2018 | 112 | 0.17 | Why? |
| Personnel Administration, Hospital | 1 | 2017 | 70 | 0.17 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.17 | Why? |
| Angina Pectoris | 1 | 2018 | 114 | 0.17 | Why? |
| Humans | 61 | 2021 | 930598 | 0.17 | Why? |
| Cardiac Care Facilities | 1 | 2017 | 79 | 0.17 | Why? |
| Stroke | 7 | 2019 | 8839 | 0.17 | Why? |
| Nitrates | 1 | 2017 | 98 | 0.17 | Why? |
| Physical Endurance | 1 | 2017 | 107 | 0.16 | Why? |
| Substance Withdrawal Syndrome | 1 | 2018 | 137 | 0.16 | Why? |
| Male | 38 | 2021 | 367725 | 0.16 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.16 | Why? |
| Diabetic Angiopathies | 1 | 2018 | 146 | 0.16 | Why? |
| Female | 39 | 2021 | 380317 | 0.16 | Why? |
| Death | 1 | 2019 | 334 | 0.15 | Why? |
| Nicotine | 1 | 2018 | 213 | 0.15 | Why? |
| Risk Assessment | 13 | 2019 | 25439 | 0.15 | Why? |
| Disease-Free Survival | 2 | 2017 | 1654 | 0.15 | Why? |
| Arteries | 1 | 2017 | 283 | 0.14 | Why? |
| Cannula | 1 | 2020 | 750 | 0.14 | Why? |
| Drug Combinations | 3 | 2019 | 3852 | 0.14 | Why? |
| Hospitalization | 10 | 2021 | 54280 | 0.14 | Why? |
| Chest Pain | 1 | 2019 | 578 | 0.14 | Why? |
| Aspirin | 2 | 2017 | 1043 | 0.14 | Why? |
| Hemodynamics | 2 | 2019 | 1562 | 0.13 | Why? |
| Treatment Outcome | 10 | 2020 | 51732 | 0.13 | Why? |
| Proportional Hazards Models | 5 | 2018 | 6543 | 0.13 | Why? |
| Blood Gas Analysis | 1 | 2017 | 893 | 0.13 | Why? |
| Heart Diseases | 3 | 2019 | 3503 | 0.13 | Why? |
| Inservice Training | 1 | 2017 | 477 | 0.13 | Why? |
| Glucose | 1 | 2017 | 573 | 0.12 | Why? |
| Plaque, Atherosclerotic | 1 | 2017 | 423 | 0.12 | Why? |
| Atherosclerosis | 2 | 2019 | 768 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2019 | 471 | 0.12 | Why? |
| Microcirculation | 1 | 2017 | 447 | 0.12 | Why? |
| Emergency Service, Hospital | 4 | 2020 | 14232 | 0.12 | Why? |
| Women's Health | 1 | 2018 | 444 | 0.12 | Why? |
| Cardiologists | 1 | 2017 | 366 | 0.12 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2017 | 398 | 0.12 | Why? |
| Coronary Artery Disease | 2 | 2017 | 2570 | 0.12 | Why? |
| Decision Support Techniques | 1 | 2019 | 903 | 0.11 | Why? |
| Heart Injuries | 1 | 2018 | 608 | 0.11 | Why? |
| Dose-Response Relationship, Drug | 4 | 2020 | 3776 | 0.11 | Why? |
| Kidney Diseases | 2 | 2019 | 1434 | 0.11 | Why? |
| Cardiovascular Agents | 1 | 2017 | 663 | 0.11 | Why? |
| Critical Care | 3 | 2020 | 14081 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.10 | Why? |
| Positive-Pressure Respiration | 1 | 2018 | 1160 | 0.10 | Why? |
| Diagnostic Imaging | 1 | 2018 | 1044 | 0.10 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.10 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.10 | Why? |
| Cardiac Output, Low | 2 | 2018 | 31 | 0.09 | Why? |
| Hypoxia | 3 | 2020 | 3626 | 0.09 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.09 | Why? |
| Benzaldehydes | 2 | 2018 | 27 | 0.09 | Why? |
| Phospholipase A2 Inhibitors | 2 | 2018 | 26 | 0.09 | Why? |
| Prognosis | 8 | 2019 | 32490 | 0.09 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.09 | Why? |
| Oximes | 2 | 2018 | 51 | 0.09 | Why? |
| American Heart Association | 2 | 2020 | 347 | 0.09 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.09 | Why? |
| Hydroxychloroquine | 3 | 2020 | 12447 | 0.09 | Why? |
| Patient Safety | 2 | 2020 | 4885 | 0.09 | Why? |
| Risk | 2 | 2019 | 5288 | 0.09 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.09 | Why? |
| Personnel Staffing and Scheduling | 1 | 2017 | 1578 | 0.09 | Why? |
| Health Status | 2 | 2019 | 3259 | 0.09 | Why? |
| Cause of Death | 2 | 2019 | 4823 | 0.09 | Why? |
| Quality Improvement | 1 | 2020 | 2435 | 0.08 | Why? |
| Noninvasive Ventilation | 1 | 2020 | 2329 | 0.08 | Why? |
| Hypoglycemic Agents | 2 | 2017 | 2165 | 0.08 | Why? |
| United States | 9 | 2021 | 46150 | 0.08 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.08 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2006 | 93 | 0.08 | Why? |
| Time Factors | 6 | 2021 | 31397 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.08 | Why? |
| Critical Illness | 3 | 2019 | 17281 | 0.08 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.08 | Why? |
| Antibodies, Monoclonal | 1 | 2005 | 8041 | 0.07 | Why? |
| Venous Thrombosis | 1 | 2020 | 2739 | 0.07 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.07 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.07 | Why? |
| Percutaneous Coronary Intervention | 3 | 2018 | 3646 | 0.07 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.07 | Why? |
| Half-Life | 1 | 2005 | 298 | 0.07 | Why? |
| Injections, Intravenous | 1 | 2005 | 381 | 0.07 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.07 | Why? |
| Patient Outcome Assessment | 2 | 2021 | 707 | 0.06 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.06 | Why? |
| Renin-Angiotensin System | 1 | 2019 | 3661 | 0.06 | Why? |
| Takotsubo Cardiomyopathy | 2 | 2020 | 453 | 0.06 | Why? |
| Education, Medical, Graduate | 1 | 2017 | 2082 | 0.06 | Why? |
| Reference Standards | 1 | 2007 | 1163 | 0.06 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.06 | Why? |
| Mortality | 2 | 2017 | 7132 | 0.06 | Why? |
| Acute Disease | 3 | 2018 | 6029 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2018 | 7330 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.06 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Anorexia Nervosa | 1 | 2002 | 103 | 0.05 | Why? |
| Proteomics | 1 | 2011 | 2481 | 0.05 | Why? |
| Emergency Medical Services | 1 | 2017 | 3557 | 0.05 | Why? |
| Bone and Bones | 1 | 2002 | 235 | 0.05 | Why? |
| Clinical Laboratory Techniques | 1 | 2007 | 23402 | 0.05 | Why? |
| Survival Rate | 3 | 2019 | 9206 | 0.05 | Why? |
| Receptor, PAR-1 | 1 | 2019 | 24 | 0.05 | Why? |
| Genomics | 1 | 2011 | 3118 | 0.05 | Why? |
| Bone Density | 1 | 2002 | 335 | 0.05 | Why? |
| Interleukin-6 | 1 | 2017 | 7522 | 0.05 | Why? |
| Vital Signs | 1 | 2021 | 257 | 0.05 | Why? |
| Venous Thromboembolism | 1 | 2017 | 4273 | 0.05 | Why? |
| Coronary Disease | 1 | 2005 | 645 | 0.05 | Why? |
| Stroke Volume | 2 | 2019 | 2153 | 0.05 | Why? |
| Organizational Objectives | 1 | 2020 | 180 | 0.05 | Why? |
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 190 | 0.04 | Why? |
| Ventricular Function | 1 | 2018 | 93 | 0.04 | Why? |
| Antimalarials | 2 | 2020 | 2505 | 0.04 | Why? |
| Visual Analog Scale | 1 | 2017 | 151 | 0.04 | Why? |
| Carbohydrate Metabolism | 1 | 2017 | 44 | 0.04 | Why? |
| Cardiac Output | 1 | 2018 | 183 | 0.04 | Why? |
| Adamantane | 1 | 2017 | 68 | 0.04 | Why? |
| Coronary Restenosis | 1 | 2018 | 153 | 0.04 | Why? |
| Dipeptides | 1 | 2017 | 106 | 0.04 | Why? |
| Diastole | 1 | 2017 | 168 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Calibration | 1 | 2017 | 307 | 0.04 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.04 | Why? |
| Single-Blind Method | 1 | 2020 | 1283 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.04 | Why? |
| Interleukin-4 | 1 | 2017 | 367 | 0.04 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.04 | Why? |
| Coronary Angiography | 1 | 2005 | 2275 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2021 | 243684 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2017 | 8207 | 0.04 | Why? |
| Myocardial Perfusion Imaging | 1 | 2017 | 218 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Boston | 1 | 2017 | 929 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Death, Sudden, Cardiac | 1 | 2018 | 522 | 0.03 | Why? |
| Ventilator Weaning | 1 | 2018 | 536 | 0.03 | Why? |
| Respiration | 1 | 2018 | 729 | 0.03 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Oxygen Consumption | 1 | 2017 | 711 | 0.03 | Why? |
| Oximetry | 1 | 2017 | 658 | 0.03 | Why? |
| Coronary Artery Bypass | 1 | 2018 | 629 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Respiration, Artificial | 1 | 2017 | 22116 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.03 | Why? |
| Exercise Tolerance | 1 | 2017 | 634 | 0.03 | Why? |
| Blood Coagulation | 1 | 2005 | 2768 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.03 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2018 | 552 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.03 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.03 | Why? |
| Indoles | 1 | 2019 | 1243 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.03 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Electrocardiography | 2 | 2018 | 3957 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.02 | Why? |
| Adult | 7 | 2020 | 244371 | 0.02 | Why? |
| Body Mass Index | 2 | 2017 | 4306 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Disease Progression | 2 | 2017 | 13580 | 0.02 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.02 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Drug Delivery Systems | 1 | 2018 | 1365 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Canada | 1 | 2019 | 6018 | 0.02 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.02 | Why? |
| Delivery of Health Care, Integrated | 1 | 2017 | 1549 | 0.02 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 72 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Intraoperative Complications | 1 | 2007 | 221 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Diet | 1 | 2017 | 2052 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.01 | Why? |
| Pyrrolidines | 1 | 2006 | 558 | 0.01 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.01 | Why? |
| Phosphates | 1 | 2002 | 135 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Syndrome | 1 | 2005 | 1310 | 0.01 | Why? |
| Reference Values | 1 | 2002 | 795 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.01 | Why? |
| Massachusetts | 1 | 2002 | 1279 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Calcium | 1 | 2002 | 708 | 0.01 | Why? |
| Adipose Tissue | 1 | 2002 | 612 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2005 | 1731 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2006 | 5440 | 0.01 | Why? |
| Regression Analysis | 1 | 2002 | 2484 | 0.01 | Why? |
| Odds Ratio | 1 | 2006 | 5861 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Surgical Procedures, Operative | 1 | 2007 | 2662 | 0.01 | Why? |
| Kidney Failure, Chronic | 1 | 2007 | 3222 | 0.01 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.01 | Why? |
| Pulmonary Embolism | 1 | 2007 | 4775 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2002 | 9893 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
| Child | 1 | 2002 | 70012 | 0.00 | Why? |